Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-22
2005-02-22
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S251000, C544S258000, C544S260000
Reexamination Certificate
active
06858612
ABSTRACT:
The present invention relates to the use of pteridine derivatives of the formula Iin which X is O or NH and R4, for example, is hydrogen, phenyl or the radical R4a—CH2— and R4a, for example, is hydrogen, (C1-C4)-alkylmercapto, the radical —NR11R12or the radical —OR13, and in which R1, R2, R3, R5, R6, R7, R11, R12and R13have the meanings given in claim1,which are nitric oxide synthase inhibitors, for the treatment of diseases which are caused by an increased nitric oxide level.
REFERENCES:
patent: 4665182 (1987-05-01), Nichol et al.
patent: 4701455 (1987-10-01), Nichol et al.
patent: 4937342 (1990-06-01), Kurono et al.
patent: 5196533 (1993-03-01), Ayling et al.
patent: 5502050 (1996-03-01), Gross
patent: 5753656 (1998-05-01), Sakai
patent: 6-56669 (1994-03-01), None
patent: 94 14780 (1994-07-01), None
patent: 95 32203 (1995-11-01), None
Macdonald, James E., Nitric Oxide Synthase Inhibitors, Annual Reports In Medicinal Chemistry, vol. 33, pp. 221-229, 1996.*
CAPLUS printout for Kojima, S., Neopterin As An Endogenous Antioxidant, Pteridines, vol. 6, No. 4, pp. 181-184, 1995.*
CAPLUS printout for Miwa et al., 6R-L-Erythro-5,6,7,8-Tetrahydrobiopterin and Dopamine Release, Pteridines, vol. 6, No. 4, pp. 173-180, 1995.*
CAPLUS printout for JP 6-56669, 1994.*
Hevel et al., Macrophage Nitric Oxide Synthase: Relationship between Enzyme-Bound Tetrahydrobiopterin and Synthase Activity, vol. 31, No. 31, pp. 7160-7165, 1992.*
Natanson, Charles, et al., “Selected Treatment for Septic Shock Based on Proposed Mechanisms of Pathogenesis”, Annals of Internal Medicine, vol. 120 (No. 9), 1994, pp. 771-783.
Werner-Falmayer et al., J. Exp. Med., vol. 172, Dec. 1990, pp. 1599-1607.
Schoedon, et al., Biochemical & Biophysical Research Communication, vol. 199, No. 2, Mar. 15, 1994, pp. 504-510.
Sakai, Naoki et al., BH4and NO Synthesis, Vo. 48(1), pp. 6-10, 1993.
Gunther, Konrad et al., Chem. Ber., 103, 1970, pp. 722-734.
Jorens, Philippe et al., Br. J., Pharmacol, 1992, 107, pp. 1088-1091.
Traub, Hermann, “Synthese Und Eigenschaften Von Tetrahydrobiopterin-Analogen Potentielle Cofaktoren Für Biologishe Hydroxylierungen”, Dissertation for the University of Konstanz, May 1987.
Ege-Serdenkci et al., Chemical Abstracts, vol. 100, 1983, Entry 33933.
Amarego et al., Chemical Abstracts, vol. 100, 1983, Entry 50980.
Amarego et al., Chemical Abstracts, vol. 98, 1983, Entry 53504.
Henning Rainer
Pfleiderer Wolfgang
Schmidt Harald
Coleman Brenda
Finnegan Henderson Farabow Garrett & Dunner LLP
Vasopharm Buitech GmbH
LandOfFree
Use of tetrahydropteridine derivatives as no synthase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tetrahydropteridine derivatives as no synthase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tetrahydropteridine derivatives as no synthase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3485467